the researchers found all regimens of anticoagulants drugs that prevent blood clotting were far superior to no anticoagulants in COVID-19 patients. More specifically, patients on both a therapeutic or full dose, and those on a prophylactic or lower dose, showed about a 50 percent higher chance of survival, and roughly a 30 percent lower chance of intubation, than those not on anticoagulants.